SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its novel immunotherapy platform, DiversitAb™, to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors and is applicable to a wide range of serious unmet needs in human diseases. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ that produce fully human antibodies targeted at specific diseases. By harnessing the native human antibody immune response, SAB’s platform enables a scalable and reliable production of these highly-efficacious polyclonal therapies with the potential to address the emergence, mutation, and diversity of modern health challenges.
The Company is executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients. Lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19, and SAB-176, a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate designed to bind to Type A and B influenza viruses. The Company continues to advance work on its Rapid Response Antibody Program collaboration with the US Department of Defense, with multiple targets and other strategic activities to help solve major health security challenges, in addition to facilitating readiness for future emerging threats. Additional pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction/rejection and early discovery work in oncology.
Data Provided by Refinitiv. Minimum 15 minutes delayed.